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Abstract
Liver transplantation for hilar cholangiocarcinoma (hCCA) has regained attention since the
Mayo Clinic reported their favorable results with the use of a neo-adjuvant chemoradiation
protocol. However, debate remains whether the success of the protocol should be attributed
to the neo-adjuvant therapy or to the strict selection criteria that are being applied. The aim
of this study was to investigate the value of patient selection alone on the outcome of liver
transplantation for hCCA. In this retrospective study, patients that were transplanted for
hCCA between1990 and 2010 in Europe were identified using the European Liver Trans-
plant Registry (ELTR). Twenty-one centers reported 173 patients (69%) of a total of 249
patients in the ELTR. Twenty-six patients were wrongly coded, resulting in a study group of
147 patients. We identified 28 patients (19%) who met the strict selection criteria of the
Mayo Clinic protocol, but had not undergone neo-adjuvant chemoradiation therapy. Five–
year survival in this subgroup was 59%, which is comparable to patients with pretreatment
pathological confirmed hCCA that were transplanted after completion of the chemoradiation
protocol at the Mayo Clinic. In conclusion, although the results should be cautiously inter-
preted, this study suggests that with strict selection alone, improved survival after transplan-
tation can be achieved, approaching the Mayo Clinic experience.
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Introduction
Hilar cholangiocarcinoma (hCCA) is a devastating cancer originating from the biliary epithe-
lium at the confluence of the right and left hepatic duct. Radical surgical resection of the tumor
is the only curative option with a chance for long term survival. Five year survival rates after
tumor resection vary between 25–40% [1–6]and occasionally, five years survival rates above
50% have been reported in a subgroup of patients undergoing elaborate surgery consisting of
extended hemihepatecomy with vascular resection.[7]
For patients with unresectable hCCA or hCCA arising in the setting of a chronic liver dis-
ease, liver transplantation theoretically enables maximum resection margins and cures an
underlying parenchymal liver disease. Unfortunately, the early experience with liver transplan-
tation for hCCA was disappointing due to low survival rates and because of shortage of donor
organs it was generally acknowledged that hCCA was not an indication for liver transplanta-
tion.[8,9]
In the last decade, however, the issue has been reconsidered mainly because of the results of
the Mayo Clinic group. The Mayo Clinic has developed a neo-adjuvant protocol consisting of
multimodal chemoradiation therapy. Patients undergo a consecutive regimen of external beam
radiation therapy together with intravenous fluorouracil (5-FU), followed by intraluminal
brachytherapy and finally oral Capecitabine while awaiting liver transplantation.[10] The early
reports were remarkably optimistic with 5 year survival rates above 80%.[10,11] In more recent
publications the survival rates have been adjusted to 65–70%, but remain unprecedented.[12]
From the beginning, the protocol has also been subjected to criticism because two separate
interventions are combined in one protocol: (a) strict selection of patients with early stage dis-
ease and (b) neoadjuvant chemoradiotherapy.[13–15] The question has emerged in the litera-
ture whether the results of the Mayo Clinic should be contributed to the selection procedure, to
the neoadjuvant chemoradiotherapy, or to the combination of both.
The aim of this study was to investigate the value of strict patient selection alone on the out-
come of liver transplantation for hCCA. For this goal, we have retrospectively applied the
Mayo Clinic selection criteria (Table 1) on patients that have undergone liver transplantation
for hCCA in Europe. The European Liver Transplant Registry was used to identify patients
transplanted for hCCA.
Materials and Methods
Patients
To identify patients who underwent liver transplantation for hilar cholangiocarcinoma, we
used the European Liver Transplant Registry (ELTR), a regularly audited registry of patients
who underwent liver transplantation in one of the 153 contributing European centers. A list
Table 1. Mayo clinic criteria for inclusion in the transplantation protocol for hilar cholangiocarcinoma
[15–17].
Diagnosis Pathologically conﬁrmed hilar cholangiocarcinoma or CA19-9 >100 ng/ml in the
presence of a radiographically malignant stricture
Tumor Tumor size < 3 cm
Distant metastases Absence of distant metastases on CT (and/or MRI) and isotope bone scan
Lymph node
metastases
Negative EUS-FNA of regional lymph nodes and negative staging laparotomy/
hand-assisted-laparoscopy with biopsy of regional lymph nodes
Abbreviations: CA 19–9; carbohydrate antigen 19–9, EUS-FNA; Endoscopic ultrasonography-ﬁne needle
aspiration.
doi:10.1371/journal.pone.0156127.t001
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was extracted from the ELTR database containing all patients that were transplanted between
1990 and 2010 for hCCA. There were 249 patients from 57 European centers. Twenty-seven
centers transplanted  2 patients. The list provided only basic variables, insufficient for in-
depth analyses. Therefore, all centers were contacted with a request to participate in the study.
Centers were preferably addressed in their own language (English, Italian, French, Swedish,
Dutch). Each center was asked to upload additional information regarding patient and tumor
characteristics and transplantation outcome by completing a webbased electronic question-
naire (SurveyMonkey, Palo Alto, California, USA) (S1 Fig). The primary outcome of this study
was overall patient survival, defined as the period between transplantation and date of death or
last follow-up (July 15th, 2013).
This study was approved by and performed under the auspices of the Board of the European
Liver and Intestine Transplant Association (ELITA), the governing society of the ELTR (S2
Fig). All patient data were retrospectively and anonymously analyzed and therefore informed
consent was not necessary. This type of research is compliant with Dutch legislation and was
retrospectively approved by our institutional Medical Ethics Review Board (S3 Fig).
Statistics
Statistical analyses were carried out using IBM SPSS Statistics, (IBM, Armonk, New York,
USA). The results are expressed as the means ±SD. Comparison of means was performed with
the Student t-test for independent samples. Comparison of categorical variables was performed
with the Chi-Square test and Fisher’s exact probability test. Five-year survival rates were calcu-
lated using the Kaplan-Meier method and the differences between groups were calculated
using the log rank test. Univariate analyses were conducted for patient survival by Kaplan-
Meier estimates of survival probabilities and the log-rank test for comparisons. A Cox propor-
tional hazard regression model was used to analyze associations with patient survival in multi-
variable analysis. P values were two-sided and values of less than 0.05 were considered
statistically significant.
Results and Discussion
Twenty-one centers uploaded data of 173 patients in the electronic database, resulting in a
response rate of 69%. All patients were transplanted between 1990 and 2010. Twenty-six
patients were excluded from the database, 12 because they were erroneously coded in the ELTR
(the indication for transplantation was not hilar cholangiocarcinoma) and 14 because hCCA
was incidentally found after liver transplantation. A study group of 147 patients remained.
Eighty-two patients were transplanted in the first decade between 1990 and 2000 and 65
patients were transplanted between 2000 and 2010.
The status of the distal bile duct margin was established in 137 patients and was tumor free
(R0 resection) in 125 patients (91.2%). Mean follow-up was 4.1 years (± 5.0).
Mayo Clinic selection criteria
The Mayo Clinic criteria for enrollment in the Mayo protocol were applied on our entire
cohort of 147 patients (Fig 1). Patients with (an attempted) resection of the tumor prior to
transplantation or percutaneous/surgical biopsy of the tumor were excluded. Endoscopic
(brush) cytology was not an exclusion criterion. Patients with lymph node metastases were also
excluded. The Mayo Clinic excludes patients with tumors>3 cm, but this does not correspond
to a particular T-stage since T-staging is based on tumor infiltration depth rather than tumor
size. Therefore, T-stage was not a part of the selection criteria in this study.
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Because the aim of this study was to assess the outcome of patients who were not treated
with neo-adjuvant chemoradiation therapy, 16 patients who did receive neo-adjuvant treat-
ment were excluded. Neo-adjuvant therapy consisted in 3 cases of monotherapy (brachyther-
apy in 2 cases and external beam radiotherapy in 1 case) and in 10 cases of combination
therapy: gemcitabine/oxaliplatin with radiotherapy (n = 4), Capecitabine and radiotherapy
(n = 3), Mayo protocol (n = 2) and not specified (n = 1). In three cases the type of neo-adjuvant
therapy was not specified.
Ultimately, 28 patients (19%) who had not been treated with neo-adjuvant chemoradiother-
apy, complied with the Mayo Clinic criteria for liver transplantation. The clinicopathological
variables of the group complying (group A) and not complying with the Mayo Clinic selection
criteria (group B) are summarized in Table 2. There were no differences between the groups,
Fig 1. Flow chart illustrating the consecutive steps that were followed to select patients whomet the
MayoClinic criteria for liver transplantation, but were not treatedwith neo-adjuvant chemoradiotherapy.
doi:10.1371/journal.pone.0156127.g001
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except for the variables on which the selection was based. Adjuvant therapy was administered
in 12 patients in group B, consisting of chemotherapy in six patients (3 patients with 5-FU, one
with Gemcitabine/oxaliplatin, one with Mytomicin and one not specified), radiotherapy in one
Table 2. Clinicopathological variables of patients undergoing liver transplantation for hilar cholangiocarcinoma. Thirty four patients who underwent
an attempt to surgically remove the tumor prior to transplantation and 8 patients with missing variables were excluded.
Variable Patients transplanted for hilar cholangiocarcinoma n = 105 P-
value
Group A n = 28 Patients complying with the Mayo Clinic
selection criteria for LT, without neo-adjuvant therapy
Group B n = 77 Patients not complying
with the Mayo Clinic selection criteria.
Mean age in years (± SD) 46 (± 9) 51 (± 10) 0.62
Gender:
Male 18 (64%) 55 (71%) 0.48
Female 10 (36%) 22(39%)
Neo-adjuvant therapy
Yes 0 (0%) 16 (21%) 0.008
No 28 (100%) 59 (79%)
Percutaneous or surgical
biopsy prior to LT
Yes 0 (0%) 35 (49%) 0.001
No 28 (100%) 36 (51%)
Adjuvant therapy
Yes 0 (0%) 12 (17%) 0.02
No 28 (100%) 60 (83%)
pT classiﬁcation
pT1 1 (4%) 6 (8%) 0.51
pT2 13 (48%) 30 (40%)
pT3 13 (48%) 35 (47%)
pT4 0 (0%) 4 (5%)
pN classiﬁcation
pN0 28 (100%) 34 (46%) 0.001
pN1 0 (0%) 37 (50%)
pN2 0 (0%) 3 (4%)
Distal bile duct margin
tumor free
Yes 26 (93%) 66 (89%) 0.58
No 2 (7%) 8 (11%)
PSC
Yes 6 (24%) NA -
No 19 (76%) NA
Median time on waiting list
in days*
30 (range: 1–870) NA -
Median preoperative CA19.9
value in kU/L**
48 (range: 4–1410) NA -
90 Day mortality
Yes 3 (11%) 13 (17%) 0.44
No 25 (89%) 64 (83%)
Abbreviations: LT: liver transplantation, PSC: primary sclerosing cholangitis, NA: not available
*Data available for 25 patients.
**Data available for 16 patients.
doi:10.1371/journal.pone.0156127.t002
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patients and a combination of chemotherapy and radiotherapy in five patients (not specified;
n = 5). We determined the use of mTOR inhibitors in postoperative immunosuppressive regi-
mens because of their potential anticancer effect. mTOR inhibitors were used in 11% of cases
in group A versus 13% in group B (P = 0.77). Data on the presence of PSC was available for 25
patients in group A: six patients (24%) had underlying PSC.
Survival
For survival analyses, patients who had undergone (an attempt at) resection of the tumor prior
to transplantation were excluded (n = 34 and missing data: n = 8) because we assumed that in
many of those cases liver transplantation was performed because of postoperative liver failure.
Actuarial 5-year survival for the entire group of 105 patients that underwent liver transplanta-
tion for hilar cholangiocarcinoma was 32%. The 90-day mortality rate was 15%.
Patients who complied with the Mayo Clinic criteria (group A) showed a significant better
survival compared to patients not complying with the Mayo selection criteria (group B). The
5-year survival rate was 59% in group A versus 21% in group B (P = 0.001) (Fig 2). In both
groups one patient was lost to follow-up, explaining the numbers at risk: 27 patients in group
A and 76 in group B. After correction for 90-day mortality (3 patients in group A) a 5-year sur-
vival rate of 67% was reached in group A.
We did not perform a comparative analysis between patients from group A and patients
that were treated with neo-adjuvant therapy because the neo-adjuvant therapy regimen in this
study was not uniform.
Fig 2. Survival analysis of patients undergoing liver transplantation for hilar cholangiocarcinoma according to
patients who complied with the Mayo Clinic criteria for liver transplantation, but were not treated with neo-
adjuvant chemoradiotherapy (group A), versus patients who not complied with the Mayo Clinic criteria (group
B). P = 0.001 (Log rank test).
doi:10.1371/journal.pone.0156127.g002
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Recurrence of disease
Data on recurrence of disease were available for 26 patients in group A and 74 patients in
group B. Mean time-to-recurrence was 7.7 (± 6.4) years in group A versus 2.8 (±4.6) years in
group B (P = 0.002). Nine of 17 deaths (53%) in group A were not attributable to tumor recur-
rence whereas in group B 22 of 61 deaths (36%) were unrelated to recurrence. Fig 3 presents
the estimated cumulative probability of recurrence over time for the two groups. At 5 years fol-
low-up, the estimated probability of recurrence was significantly lower in group A (46%) com-
pared to group B (79%) (P = 0.002).
Univariate and multivariate analyses
Results of univariate analysis of variables associated with survival are presented in Table 3.
Patients who had undergone (an attempt at) resection of the tumor prior to transplantation were
excluded (n = 34 and missing data: n = 8). Only lymph node status was found to be of significant
influence on 5-year survival rate (43% in patients with pN0 disease versus 16% in patients with
pN1 disease, P = 0.002). The adjusted hazard ratio for positive lymph node status, calculated in a
Cox regression analysis, was 2.09 (95%-Confidence interval: 1.31–3.34. P = 0.002).
Discussion
With the introduction of a neo-adjuvant chemoradiation protocol, liver transplantation for
patients with unresectable hCCA or hCCA arising in the setting of PSC has been re-introduced.
The concept was pioneered by the team at the University of Nebraska[18] and embraced and
Fig 3. Cumulative probability of recurrence of disease after liver transplantation for hilar cholangiocarcinoma
according to patients who complied with the Mayo Clinic criteria for liver transplantation, but were not treated
with neo-adjuvant chemoradiotherapy (group A), versus patients who not complied with the Mayo Clinic
criteria (group B). P = 0.002 (Log rank test).
doi:10.1371/journal.pone.0156127.g003
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modified by the Mayo Clinic group in Rochester. Today more centers are adopting the proto-
col. [19] However, from the beginning, the question has emerged in the literature whether the
strict selection criteria that are being applied to enter the protocol are more important for the
success of the program than the neo-adjuvant chemoradiotherapy itself.[13] Further, It should
be noted that the use of the protocol is not without risk and is associated with a 40% rate of vas-
cular complications secondary to the high-dose external beam radiation therapy and brachy-
therapy.[20] This study was undertaken to evaluate the impact of selection alone, without the
use of neo-adjuvant therapy, on the outcome of patients transplanted for hilar cholangiocarci-
noma in Europe. In this retrospective cohort a five year survival rate of 59% was found in
patients that complied with the Mayo Clinic criteria for liver transplantation, but had not
undergone neo-adjuvant chemoradiotherapy. To adequately interpret these results, a number
of issues should be addressed.
First, not all selection criteria could be directly translated to our cohort. The Mayo Clinic
does not accept patients with a tumor size> 3 cm for liver transplantation. Since we had no
information about tumor size and tumor size does not correspond to a particular T-stage, we
accepted all T-stages in our selected subgroup. In accordance with the Mayo Clinic, we
excluded patients with regional lymph node metastases and those who had undergone invasive
attempts for tissue diagnosis (surgical or percutaneous biopsy). Endoscopic brushings to con-
firm the diagnosis was not considered an exclusion criterion. A positive distal bile duct margin
was, comparable to the Mayo series, also not an exclusion criterion.
Table 3. Univariate analysis for five-year survival in patients transplanted for hilar cholangiocarcinoma. Thirty four patients who underwent an
attempt to surgically remove the tumor prior to transplantation and 8 patients with missing variables were excluded.
Variable Total number of patients 5-year survival (%) P-value
Age (yr)
<60 85 (83%) 33 0.24
>60 18 (17%) 25
Gender
Male 71 (69%) 28 0.35
Female 32 (31%) 42
Neo-adjuvant therapy
Yes 16 (16%) 34 0.37
Male 85 (84%) 31
Adjuvant therapy
Yes 12 (12%) 33 0,47
No 86 (88%) 34
pT-classisﬁcation
Early stage (pT1,2) 50 (50%) 31 0.72
Late stage (pT3,4) 51 (50%) 35
pN-classiﬁcation*
pN0 61 (63%) 43 0.002
pN1 36 (37%) 16
Radical resection
Yes 90 (90%) 34 0,79
No 10 (10%) 23
*Three patients with pN2 disease were excluded from the analysis
doi:10.1371/journal.pone.0156127.t003
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Second, it was shown that the improvement in survival of patients complying with the
Mayo Clinic selection criteria (group A) was attributable to a superior oncological outcome,
because these patients also demonstrated a significant lower tumor recurrence probability.
Third, the five-year survival rate of 59% in group A is still slightly less than the five-year sur-
vival rates of 65–70% reported in the Mayo Clinic series. However, not all patients (around
50%) enrolled in Mayo Clinic series had pathological confirmation of hCCA at the start of neo-
adjuvant therapy.[15] It is well known that the diagnosis of hCCA can be difficult because
endoscopic brushings or biopsies are often negative or inconclusive.[21] Therefore, the Mayo
Clinic group also accepts patients with a malignant-appearing stricture on percutaneous or
endoscopic cholangiography and at least one of the three following criteria: polysomy on fluo-
rescent in situ hybridization; or CA-19.9> 100 U/mL; or a mass on cross-sectional imaging at
the site of the stricture. A recent publication from the Mayo Clinic group addressing this issue,
showed that patients with pretreatment pathological confirmation of hCCA arising in the set-
ting of PSC, have a significant worse 5-year survival compared to patients without pathological
confirmation (66 vs 92%).[15] In patients with hCCA arising de novo, 5-year survival rates in
the group with and without pretreatment pathological confirmation were comparable: 63%
and 65% respectively. In addition, a recent publication from Duignan et al[22] in which their
experience with the Mayo protocol in patients with pathological confirmed hCCA was
reported, showed a 4-year survival rate of 60%.These survival rates are similar to the 5-year sur-
vival rate of 59% in our subgroup of patients complying with the Mayo criteria.
In our cohort lymph node status was found to be the only significant factor for survival in
univariate analysis. We believe that identification of lymph node metastases is probably the
most important step in selecting patients with hCCA for liver transplantation.
Obviously, the current study has a number limitations related to its retrospective and multi-
center design. First, a response rate of 37% of the contacted centers is not very high, but the 21
centers that did participate, reported 69% of the total amount of patients that were transplanted
between 1990 and 2010 according to the ELTR. Because we approached all centers for addi-
tional information, we believe the obtained data is very reliable. To achieve the highest possible
response rate, we deliberately developed a short questionnaire lowering the threshold for cen-
ters to reply. Twenty-seven centers transplanted only one or two patients and because we
assumed that the tumors in this group would comprise mainly of incidentalomas, these centers
were not vigorously approached in case they did not reply.
Second, 21% of patients in group B underwent neo-adjuvant therapy and 17% underwent
adjuvant therapy. Unfortunately it was not possible to conduct analyses between these sub-
groups and group A, because the (neo-)adjuvant protocols in group B were too heterogeneous.
Based on our study, no statements can be made about the effect of (neo-)adjuvant therapy on
the outcome of liver transplantation for hCCA.
Third, the present study is based on data from the ELTR. Centers performing liver trans-
plantation report their cases and diagnoses to the ELTR. However, if this has been omitted for
any reason, the patient was subsequently lost to our survey.
Conclusions
In conclusion, this study reports the ELTR experience of liver transplantation for hilar cholan-
giocarcinoma without the use of neo-adjuvant therapy. It was shown that selection is vital to
improve the outcome of these patients. Regional lymph node status was identified as an inde-
pendent prognostic factor for survival. A subgroup analysis of selected patients, meeting the
Mayo Clinic criteria for liver transplantation resulted in a 5-year survival rate of 59% which
closely approaches the survival rates of 63–66% reported by the Mayo Clinic for patients with
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pretreatment pathological confirmation of hCCA. Although the data should be cautiously
interpreted because of the retrospective study design, our study suggests that selection is more
important than neo-adjuvant therapy. However, the final answer should come from a random-
ized trial, as was already suggested by Bismuth in 2000.[13]
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